NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired TG Therapeutics, Inc. (NASDAQ:TGTX) securities between September 15, 2014 and October 12, 2016 (the “Class Period”). Investors have until March 7, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The Complaint alleges that throughout the Class Period, TG Therapeutics misrepresented and/or omitted material information concerning its GENUINE Phase III clinical trial for its proprietary combination of drug therapies TG-1101 and TGR-1202. The Phase III trial consisted of two parts – Part I evaluating the effect of TG-1101 and ibrutinib on overall response rate in approximately 200 patients and Part II evaluating the effect of TG-1101 and ibrutinib on progression-free survival in all study patients.
During the class period, TG Therapeutics repeatedly assured investors as to the efficacy and potential FDA approval of the treatment, referring to it as a “best-in-class treatment.” Then, on October 13, 2016, TG Therapeutics announced that it would abandon Part II of the study and cut target enrollment for its Phase III trial, thus annulling its filed Special Protocol Assessment with the FDA and increasing the likelihood that the FDA would not approve the combination treatment. Following this news, TG Therapeutics shares declined $2.24 per share, or over 27%, from $8.25 per share on October 12, 2016 to $6.01 per share on October 17, 2016.
If you purchased or otherwise acquired TG Therapeutics securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact J. Brandon Walker, Esq. by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm, concentrating in commercial and securities litigation. For additional information concerning the TG Therapeutics lawsuit, please go to www.bespc.com/tg-therapeutics. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.